Hyper- and Hypokalemic Periodic Paralysis Study

PHASE3CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
Hyperkalemic Periodic ParalysisHypokalemic Periodic Paralysis
Interventions
DRUG

Dichlorphenamide (double-blind)

50mg tablet; maximum dosage 400mg/day

DRUG

Placebo (double-blind)

Inactive substance manufactured to look like Dichlorphenamide 50mg tablet

DRUG

Dichlorphenamide (open-label)

50mg tablet; maximum dosage 400mg/day

Trial Locations (12)

10032

Columbia University Medical Center, New York

14642

University of Rochester, Rochester

43210

Ohio State University, Columbus

55905

Mayo Clinic, Rochester

63110

Washington University School of Medicine, St Louis

66160

University of Kansas Medical Center, Kansas City

75390

University of Texas Southwestern-Dallas, Dallas

90095

UCLA Neurology, Los Angeles

94143

University of California-San Francisco, San Francisco

02115

Brigham & Women's Hospital, Boston

Unknown

University of Milan, San Donato

Institute of Neurology-Queen's Square, London

All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

University of Rochester

OTHER

NCT00494507 - Hyper- and Hypokalemic Periodic Paralysis Study | Biotech Hunter | Biotech Hunter